EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) has entered the age of individual treatment, and increasing point mutations of specific oncogenes and rearrangement of some chromosomes are biomarkers used to predict the therapeutic effect of targeted therapy. At present, there is a consensus among clinicians that...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Shu, Wang, Zhehai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189714/
https://www.ncbi.nlm.nih.gov/pubmed/25302015
http://dx.doi.org/10.2147/DDDT.S69690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189714/
https://www.ncbi.nlm.nih.gov/pubmed/25302015
http://dx.doi.org/10.2147/DDDT.S69690

Ejemplares similares